PT Benteng Api Technic Tbk (IDX:BATR)
Indonesia · Delayed Price · Currency is IDR 82.00
-2.00 (-2.38%)
Aug 1, 2025, 3:47 PM WIB
Verve Therapeutics Income Statement
Financials in millions IDR. Fiscal year is January - December.
Millions IDR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 109,598 | 107,361 | 138,149 | 131,345 | 81,378 | 77,250 | |
Revenue Growth (YoY) | -20.67% | -22.29% | 5.18% | 61.40% | 5.34% | - |
Cost of Revenue | 76,505 | 74,862 | 95,201 | 97,818 | 60,061 | 57,590 |
Gross Profit | 33,093 | 32,499 | 42,949 | 33,526 | 21,317 | 19,660 |
Selling, General & Admin | 12,284 | 13,383 | 18,395 | 15,505 | 12,728 | 12,157 |
Other Operating Expenses | -1,780 | -2,213 | -251.18 | 728.07 | 732.54 | 546.79 |
Operating Expenses | 10,504 | 11,170 | 18,144 | 16,234 | 13,461 | 12,704 |
Operating Income | 22,590 | 21,329 | 24,805 | 17,293 | 7,857 | 6,956 |
Interest Expense | -3,462 | -3,082 | -2,360 | -2,262 | -2,786 | -1,893 |
Interest & Investment Income | - | - | - | 290.42 | 358.18 | 152.5 |
Currency Exchange Gain (Loss) | -250.12 | -199.04 | 125.16 | -3.76 | 88.02 | 125.13 |
Other Non Operating Income (Expenses) | -71.02 | -156.73 | -291.92 | -464.65 | -712.63 | -541.61 |
EBT Excluding Unusual Items | 18,807 | 17,891 | 22,278 | 14,852 | 4,804 | 4,800 |
Gain (Loss) on Sale of Assets | 163.59 | 163.59 | - | - | - | - |
Asset Writedown | -6,351 | -6,351 | -7,190 | - | - | - |
Pretax Income | 12,620 | 11,704 | 15,088 | 14,852 | 4,804 | 4,800 |
Income Tax Expense | 2,036 | 1,717 | 969.5 | 2,505 | 1,503 | 709.39 |
Earnings From Continuing Operations | 10,583 | 9,986 | 14,118 | 12,347 | 3,301 | 4,090 |
Minority Interest in Earnings | -8.25 | 7.17 | -256.56 | -639.62 | -14.71 | -169.11 |
Net Income | 10,575 | 9,994 | 13,862 | 11,707 | 3,286 | 3,921 |
Net Income to Common | 10,575 | 9,994 | 13,862 | 11,707 | 3,286 | 3,921 |
Net Income Growth | -23.71% | -27.91% | 18.40% | 256.30% | -16.20% | - |
Shares Outstanding (Basic) | 2,752 | 2,752 | 2,752 | 644 | 33 | 33 |
Shares Outstanding (Diluted) | 2,752 | 2,752 | 2,752 | 644 | 33 | 33 |
Shares Change (YoY) | - | - | 327.70% | 1880.00% | - | - |
EPS (Basic) | 3.84 | 3.63 | 5.04 | 18.19 | 101.10 | 120.65 |
EPS (Diluted) | 3.84 | 3.63 | 5.04 | 18.19 | 101.10 | 120.65 |
EPS Growth | -23.71% | -27.91% | -72.32% | -82.00% | -16.20% | - |
Free Cash Flow | -41,203 | -78,100 | 12,247 | -2,968 | 6,071 | 7,718 |
Free Cash Flow Per Share | -14.97 | -28.38 | 4.45 | -4.61 | 186.80 | 237.46 |
Dividend Per Share | 1.410 | 1.410 | - | - | - | - |
Gross Margin | 30.20% | 30.27% | 31.09% | 25.52% | 26.20% | 25.45% |
Operating Margin | 20.61% | 19.87% | 17.95% | 13.17% | 9.65% | 9.01% |
Profit Margin | 9.65% | 9.31% | 10.03% | 8.91% | 4.04% | 5.08% |
Free Cash Flow Margin | -37.59% | -72.75% | 8.87% | -2.26% | 7.46% | 9.99% |
EBITDA | 26,567 | 25,050 | 27,771 | 19,992 | 10,290 | 9,775 |
EBITDA Margin | 24.24% | 23.33% | 20.10% | 15.22% | 12.65% | 12.65% |
D&A For EBITDA | 3,978 | 3,721 | 2,966 | 2,699 | 2,434 | 2,818 |
EBIT | 22,590 | 21,329 | 24,805 | 17,293 | 7,857 | 6,956 |
EBIT Margin | 20.61% | 19.87% | 17.95% | 13.17% | 9.65% | 9.01% |
Effective Tax Rate | 16.14% | 14.67% | 6.43% | 16.87% | 31.29% | 14.78% |
Advertising Expenses | - | 247.98 | 391.18 | 58.97 | 36.84 | 51.11 |
Updated Oct 31, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.